6 completed, 2 withdrawn, 1 enrolling by invitation, 1 recruiting. 4 Phase 2, 2 Phase 3, 2 Phase 4, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Completed 2 |
| Early Phase 1 | 1 | Enrolling by invitation 1 |
Follow AgelessRx: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Gerotherapeutic Interventions for Healthspan Improvement Rapamycin, Naltrexone, Metformin - Healthspan Improvement, Aging | Phase 3 | Completed | AgelessRx | 26 | 2025-07-23 | 2026-10-30 |
| Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation Metformin, Rapamycin, Naltrexone - Longevity, GLP-1 | Phase 2 / Phase 3 | Recruiting | AgelessRx | 150 | 2024-12-17 | 2025-07-30 |
| Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures GLP-1, Placebo - Longevity, Quality of Life | Early Phase 1 | Enrolling by invitation | AgelessRx | 150 | 2024-11-01 | 2025-07-30 |
| The Efficacy and Tolerability of Canagliflozin in Healthy Individual Invokana Pill - Healthy Aging | Phase 4 | Completed | AgelessRx | 30 | 2024-02-12 | 2024-07-19 |
| The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals Rapamycin - Aging | Completed | AgelessRx | 67 | 2023-04-25 | 2024-08-13 | |
| The Efficacy and Tolerability of Acarbose in Healthy Individuals Acarbose Tablets 50mg - Tolerance, Side Effect | Phase 4 | Completed | AgelessRx | 15 | 2022-08-10 | 2023-07-27 |
| The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging low-dose naltrexone - Aging | Withdrawn | AgelessRx | 2022-03-14 | 2024-08-06 | ||
| Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19 Metformin, Naltrexone - Covid19 | Phase 2 | Withdrawn | AgelessRx | 2021-02-01 | 2022-10-04 | |
| Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome Naltrexone, NAD+ - Covid19, Long COVID-19 | Phase 2 | Completed | AgelessRx | 36 | 2021-01-28 | 2023-01-25 |
| Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study Rapamycin, Placebo - Aging | Phase 2 | Completed | AgelessRx | 129 | 2020-01-01 | 2024-01-24 |
COVID-19 (2) · Agnosia (1) · Inflammation (1) · Post-Acute COVID-19 Syndrome (1)
Naltrexone (5) · Sirolimus (4) · Metformin (3) · NAD (2) · Acarbose (1) · Ascorbic Acid (1) · Canagliflozin (1) · Glucagon-Like Peptide 1 (1) · Glutathione (1) · Vitamin B 12 (1) · mecobalamin (1) · semaglutide (1)
United States (10)
Sajad Zalzala, MD (6) · Stefanie Morgan, PhD (2) · James P Faber (1) · James Watson, MD (1) · Jenell Decker, MD (1)